Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis Monotherapy (Ranibizumab 0.5 mg Intravitreal Injections) Compared With Lucentis Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy

Trial Profile

Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis Monotherapy (Ranibizumab 0.5 mg Intravitreal Injections) Compared With Lucentis Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2016

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Diabetic retinopathy
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Mar 2013 Planned end date changed from 1 Aug 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 07 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top